Institute Of Oncology Prof. Dr. Ion Chiricuta Cluj-Napoca — Clinical Trial Site

218 Registered trials

96 Currently recruiting

Organisation

Institute Of Oncology Prof. Dr. Ion Chiricuta Cluj-Napoca

Location

Cluj-Napoca, Romania

Identifier

ORG-100042218

Address

Strada Republicii 34-36, 400015, Romania

Departments

#2117: Hematology
#98350010:Oncology
040010: Radioterapie I
164203: Hematology
2303:Oncologie Medicala
3004: Hematology
3200:Oncologie Medicala
3201: Radiotherapy Department
3307: Hematology
6102: Radiotherapy
6106:Oncologie Medicala
6703: Oncology
93150009: Oncologie Medicala
AEM in colab.with Inst.of Onc.Pr.Dr.I.Chiricuta,Med.Onc.I-Hosp.Build.4th fl,Wrds 329,330,331
ARENSIA Exploratory Medicine SRL in collaboration with ”Prof.Dr.Ion Chiricuta” Institute of Oncology
Breast Cancer Centre
Breast tumor center
Centrui de Tumori Mamare
Departament Oncologie Medicala
Departamentul de Oncologie Medicala
Department of Hematology
Department of Medical Oncology
Department of Oncology
Dept of Medical Oncology
Haematology
Haematology Department
Hematologie
Hematology
Hematology Clinic
Hematology department
Institutul Oncologic Prof Dr I Chiricuta
Internal Medicine
Medical
Medical Oncology
Medical Oncology department
Medical Oncology I
N/A
NA
Oncologie
Oncologie Generala si Chimioterapie
Oncologie Medicala
Oncologie Medicala - Radioterapie I
Oncologie Medicala II
Oncology
Oncology department
Phase 1 Unit AEM in collab with IOCN, Radiotherapy departament
Phase 1 Unit, Radiotherapy
Radioterapie
Radioterapie 1
Radioterapie I
Radioterapie I - Oncologie
Radiotherapy
Radiotherapy Department
Radiotherapy I
Radiotherapy III
ROU006: Oncologie Medicala
ROU008: Oncology
Secția Clinica Hematologie
Sectia de Hematologie
Sectia Hematologie
Sectia Oncologie Medicala
Sectia Oncopediatrie
Specialist in Hematology
Surgery II
Urologie

Clinical trials at this site (218)

Search interface

Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants With Recurrent KRAS/NRAS and BRAF Wild-type Colorectal Cancer Recruiting

2024-513853-66-00 KRAS/NRAS and BRAF Wildtype Recurrent, Unresectable or 5 2025-02-04
Phase 1, open-label, multicenter, dose escalation study of SRG-1505 as monotherapy in subjects with mature b-cell malignancies Recruiting

2023-505204-34-00 Mature B-Cell Neoplasm, Non-Hodgkin Lymphoma, Diffuse l 1 2024-12-30
A Phase 1 Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PAS-004, a MEK (1/2) Inhibitor, in … Recruiting

2024-510900-34-00 Solid Tumors 1 2024-11-22
MK-1084 with Pembrolizumab in 1L Locally Advanced or Metastatic NSCLC With KRAS G12C Mutations and PD-L1 ≥50% Recruiting

2023-507776-42-00 Non-small cell lung cancer 5 2024-11-14
A phase 3 trial comparing a therapeutic cancer vaccine OSE2101 to chemotherapy docetaxel in patients with metastatic Non-Small Cell Lung Can… Recruiting

2023-509340-10-00 Patients with HLA-A2 positive phenotype and metastatic 5 2024-10-29
A study to learn more about how well sevabertinib works and how safe it is compared with standard treatment, in participants who have advanc… Recruiting

2024-511319-91-00 Advanced non-small cell lung cancer with HER2 (ERBB2) m 5 2024-10-23
Adding Navtemadlin to Ruxolitinib for Patients with Myelofibrosis Recruiting

2023-504724-25-00 Primary Myelofibrosis 5 2024-10-16
A first-in-human study to investigate the safety and tolerability of a new antibody-guided drug delivery treatment for patients with therapy… Recruiting

2024-511074-80-01 Platinum-resistant high-grade ovarian cancer (PROC) or 7 2024-09-06
Phase Ib Open Label Basket Trial of RAY121 to Inhibit Classical Complement Pathway in Immunological Diseases (RAINBOW Trial) Recruiting

2023-507692-21-00 Bullous pemphigoid 3 2024-08-22
A Global Multicenter, Open Label, Randomized Phase 3 Registrational Study of Lisaftoclax (APG-2575) in Previously Treated Patients with Chro… Recruiting

2023-508005-24-00 Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 5 2024-08-01
STUDY OF OP-1250 ADMINSTERED AS MONOTHERAPY AND COMPARED TO STANDARD OF CARE FOR THE TREATMENT OF ER+, HER2– ADVANCED OR METASTATIC BREAST C… Recruiting

2023-505871-63-00 ER+, HER2- metastatic breast cancer following endocrine 5 2024-04-08
A Global Pivotal Placebo-Controlled Study of LY3537982 in Combination with Pembrolizumab and LY3537982 in Combination with Pembrolizumab, Pe… Recruiting

2023-503412-33-00 Stage IIIB-IIIC or Stage IV KRAS G12C-mutant non-small 5 2024-03-29
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) Recruiting

2023-504031-41-00 ER+/HER2- Early Breast Cancer 5 2024-03-25
A Randomized, Multicenter, Placebo-controlled, Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF)… Recruiting

2023-504323-25-01 breast cancer 5 2024-03-19
A study to Evaluate Efficacy and Safety of Giredestrant Compared with Fulvestrant (plus a CDK4/6 inhibitor), in Participants with ER+ HER2-N… Recruiting

2022-502980-39-00 Estrogen receptor (ER)-positive, HER2-negative advanced 5 2024-01-25
A Randomized, Multi-Center, Parallel, Double-Blinded, Placebo-Controlled Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics o… Recruiting

2022-502193-16-00 Chronic lymphocytic leukemia, Multiple Myeloma and Non- 5 2023-11-14
Iberdomide Manteinance Versus Lenalidomide Manteinance Therapy Following Autologous Stem Cell Transplant in Participants with NDMM Recruiting

2022-501515-14-00 Newly Diagnosed Multiple Myeloma (NDMM) 5 2023-09-29
A Study in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) to Evaluate How Safe Long-term Treatment with Pozelimab + Cemdisira… Recruiting

2023-510336-36-00 Paroxysmal nocturnal hemoglobinuria (PNH) 5 2023-05-05
A study to Investigate the efficacy and safety of Depemokimab compared with placebo in Adults with Hypereosinophilic Syndrome (HES) Recruiting

2023-510346-25-00 Hypereosinophilic Syndrome (HES) 5 2022-09-01
Asciminib Roll-over Study Recruiting

2023-507557-16-00 chronic myelogenous leukemia (CML) or Philadelphia Chro 5 2022-08-31
Randomised phase III trial of ADT +/- darolutamide in frail men with castration-naïve de novo metastatic prostate cancer Recruiting

2022-502425-18-00 Adenocarcinoma of the prostate 5 2022-04-19
Study to Evaluate the PK and Safety of Oral Decitabine and Cedazuridine in Cancer Patients with Renal Impairment Recruiting

2024-516291-16-00 Acute myeloid lymphoma (AML), myelodysplastic syndrome 3 2021-10-26
A Phase 1/2a, First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of HDP-101 in Patients with Plasma C… Recruiting

2024-515273-10-00 Relapsed or refractory Multiple Myeloma (r/r MM) 7 2021-10-19
A First-in-Human Study to Evaluate the Safety and Anti-cancer Activity of the product FS222, which is an Antibody medication, in Subjects wi… Recruiting

2024-514010-12-00 Advanced Malignancies 1 2020-12-03